Iovance Biotherapeutics (IOVA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Key Insights
Critical company metrics and information
Share Price
$8.63Market Cap
$2.63 BillionTotal Outstanding Shares
304.78 Million SharesTotal Employees
557Dividend
No dividendIPO Date
October 15, 2010SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.iovance.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $41.95 Million |
Net Cash Flow From Investing Activities, Continuing | $-48.80 Million |
Net Cash Flow From Operating Activities | $-58.97 Million |
Net Cash Flow From Operating Activities, Continuing | $-58.97 Million |
Exchange Gains/Losses | $1.25 Million |
Net Cash Flow, Continuing | $-65.82 Million |
Net Cash Flow From Investing Activities | $-48.80 Million |
Net Cash Flow From Financing Activities, Continuing | $41.95 Million |
Net Cash Flow | $-64.57 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Gross Profit | $18.73 Million |
Operating Expenses | $107.80 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-83.54 Million |
Net Income/Loss | $-83.54 Million |
Costs And Expenses | $147.62 Million |
Operating Income/Loss | $-89.07 Million |
Research and Development | $68.25 Million |
Net Income/Loss Attributable To Parent | $-83.54 Million |
Diluted Earnings Per Share | $-0.28 |
Other Operating Expenses | $39.55 Million |
Diluted Average Shares | $303,269.00 |
Revenues | $58.55 Million |
Basic Average Shares | $303,269.00 |
Benefits Costs and Expenses | $143.62 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit, Deferred | $-1.52 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Cost Of Revenue | $39.82 Million |
Basic Earnings Per Share | $-0.28 |
Income/Loss From Continuing Operations Before Tax | $-85.06 Million |
Income/Loss From Continuing Operations After Tax | $-83.54 Million |
Income Tax Expense/Benefit | $-1.52 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $773.46 Million |
Current Liabilities | $118.06 Million |
Noncurrent Assets | $492.54 Million |
Liabilities And Equity | $991.12 Million |
Current Assets | $498.58 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Liabilities | $99.60 Million |
Inventory | $38.58 Million |
Fixed Assets | $112.52 Million |
Other Non-current Assets | $380.02 Million |
Other Current Liabilities | $86.37 Million |
Accounts Payable | $31.69 Million |
Equity | $773.46 Million |
Assets | $991.12 Million |
Other Current Assets | $460.00 Million |
Liabilities | $217.66 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.